Skip to search formSkip to main contentSkip to account menu

Indapamide / Perindopril

Known as: indapamide, perindopril drug combination, perindopril indapamide, perindopril+indapamide 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Antihypertensive AgentsDrug CombinationsIndapamidePerindopril

Narrower (2)

PreteraxS5590

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Analysis of Preferences in the Use of Fixed-Doses Combinations Antihypertensive Drugs in the Regions of Far-Eastern Federal District
Background Diseases characterized by elevated blood pressure are the most frequently diagnosed pathology among socially… 
2014
2014
Хроническая болезнь почек как фактор риска атеросклероза у больных системной красной волчанкой
Last years development of an atherosclerosis in systemic lypus erythematosis patients is proved. Prevalence of risk factors of… 
2011
2011
COMPARATIVE EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION ACCOMPANIED BY TYPE 2 DIABETES
Aim. To compare efficacy of different fixed antihypertensive combinations in achievement of the target level of blood pressure… 
2008
2008
The impact of one or two missed doses on the duration of action of combined perindopril and indapamide
Figure 2 Changes in mean±s.d. 24-h ambulatory systolic and diastolic blood pressure versus baseline during the first 24 h after… 
2007
2007
The impact of one or two missed doses on the duration of action of combined perindopril and indapamide
To evaluate the persistence of the antihypertensive effect of perindopril 4 mg+indapamide 1.25 mg once daily for up to 72 h using… 
2007
2007
The clinical efficiency and safety of perindopril indapamide in elderly patients with mild to moderate essential hypertension
Objective: To investigate the efficacy and safety of perindopril/indapamide(Biprel) elderly patients with mild to moderate… 
2007
2007
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
The Action in Diabetes and vascular disease: preterAx and diamicoN-MR Controlled Evaluation (ADVANCE) trial was designed to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)